Skip to main content
. Author manuscript; available in PMC: 2023 Jun 22.
Published in final edited form as: Addict Biol. 2021 Oct 29;27(1):e13108. doi: 10.1111/adb.13108

Figure 4. Effects of Strychnine and Ro15–4513 on EtOH inhibition of evoked DA release in vivo.

Figure 4.

(A) Representative example of the effects of EtOH (2 g/kg; IP; Also shown in Fig. 1D) on evoked DA release in the NAc of an isoflurane-anesthetized mouse. In this example, EtOH inhibited the DA signal approximately 50%. Inset shows superimposed I vs t recordings before and after EtOH. (B) Representative example of the effects of strychnine (1 mg/kg) on 2.0 g/kg EtOH inhibition of evoked DA release. In this example, intraperitoneal administration of strychnine blocked the typical inhibition by EtOH. Inset shows superimposed I vs t recordings before and after strychnine and strychnine+EtOH. (C) Representative example of the effects of the α4β3δ GABAAR antagonist Ro15–4513 (Ro15) on 2.0 g/kg EtOH inhibition of evoked DA release in the NAc. Insets shows representative superimposed I vs t plots before and after Ro15 and Ro15+EtOH. (D) Summary of strychnine and Ro15 on 80 mM EtOH inhibition of evoked DA release. Values in parentheses represent n values. (E) Summary of EtOH effects in δ-KO vs WT mice. Knock-out mice were resistant to EtOH inhibition of evoked DA release. Asterisks *,*,*** indicate significance levels p<0.05, p<0.01, and p<0.001, respectively.